Background: ClincalTrials.gov and the database for Aggregate Analysis of ClincalTrials.gov (AACT)

Similar documents
AACT-Results: The Results dataset extensions for the AACT database

POLICY AND PROCEDURE MANUAL

Compliance Department RESEARCH COMPLIANCE MEMORANDUM

Clinical Trials: Registration, Results Reporting, and Data Sharing

10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.

Not My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center

ClinicalTrials.gov Registration Guide

April 13, Background

Acting Deputy Commissioner for Operations, U.S. Food and Drug Administration

NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information

Fergus Sweeney, European Medicines Agency

Topics. Safety First Initiative. Drug Safety Communications DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION

Compliance with Results Reporting at ClinicalTrials.gov

Joint statement on public disclosure of results from clinical trials

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE

CLINICAL TRIALS AND MARKET RESEARCH

Office for Human Subject Protection. University of Rochester

Trial Reporting in ClinicalTrials.gov The Final Rule

How is trial registration affecting gjournals?

Data & Materials Sharing Agreement. Collaboration for AIDS Vaccine Discovery. Clinical Trials Data Sharing Addendum & Related Information

CDISC Standards: Current and Future

Update on Real World Evidence Data Collection

Yale University. Open Data Access Project

The Future of Drug Safety

Good Clinical Practice (GCP) & Clinical Trial Registries

Welcome to the 6 th Annual Meeting of ISMPP

Public release of clinical information in drug submissions and medical device applications

Clinical Trial Transparency UK perspective

FDA > CDRH > CFR Title 21 Database Search

FDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives

EFPIA layperson summary Principles that apply to Clinical Trial Transparency. Antonio Ferrari (Chiesi) & Solange Rohou (AZ)

Guiding Principles on the Sharing of Clinical Trial Data. DNDi POLICIES

In its effort to develop worldwide

Overcoming Statistical Challenges to the Reuse of Data within the Mini-Sentinel Distributed Database

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

FDA Sponsor and Investigator Responsibility Checklist

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

PHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008

Recommendations for Strengthening the Investigator Site Community

Health Industry Alert

COVER PAGE. Title: Regulatory Implications of Data-mining Author: Renee Harrell Word Count: 2387 COVER PAGE

IND IND ACKNOWLEDGEMENT

FDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency

Office Of Clinical Trials. Christine Nelson, RN, BSN, MBA, CCRC

Putting CDISC Standards to Work How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY

The Intersection of Genomics Research and the IDE Regulation

October, Integration and Implementation of CDISC Standards

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

FDA Guidance, Clinical Pharmacology, and Regulatory Science

Pharmacovigilance & Signal Detection

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Clinical Trial/Results Disclosure. Edward Paluch, PhD & Peter Rittenhouse, PhD Complete Healthcare Communications, Inc.

Bayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

Pharmacovigilance and the Generic Industry. Mark Vieder RPh MBA Director, Safety & Medical Writing Biorasi

Sunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners. Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX

Responsibility, Sustainability & Public Trust

Canadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines

SERIOUS ADVERSE EVENTS

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015

Recent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility

Long-Term Follow-Up in Gene Transfer Clinical Research

Getting Connected: The Benefits of a Unified Clinical Platform

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?

Expanded Access to Investigational Imaging Drugs

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION

Calculating the Direct and Indirect Costs of a Phase III HABP/VABP Clinical Study Stella Stergiopoulos Senior Project Manager Tufts CSDD

The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing

THE NEW ZEALAND MEDICAL JOURNAL

Under this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at

CTTI Overview One Decade of Impact. One Vision Ahead.

RE: FDA-2011-N-0090: Food and Drug Administration; Unique Device Identification System

Adis Journals Overview

UDI: From Compliance to Value OMTEC June 2013 Karen Conway

What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

External IRB Review What Does it Mean for Your Institution

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective

Clinical Research at MSU

Food and Drug Administration (FDA) 101

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

Two-Dimensional (2D) Vaccine Barcode Pilot Project

CDISC Journal. Current status and future scope of CDISC standards. By Rebecca D. Kush, President and CEO, CDISC. 1. Introduction

Clinical Trials application process, legislation & guidelines

The European Network of Centres of Pharmacoepidemiology & Pharmacovigilance (ENCePP)

Speed your time to market with FDA s expedited programs

Editor-in-Chief, 23rd March 2017

Volunteering for Clinical Trials

Views of a Clinical Study Report

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network

Expanded Access (including Emergency Use & Humanitarian Use Devices)

Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children Natalie Pica, MD, PhD, a, b Florence Bourgeois, MD, MPHa, c, d

21 st Century Cures Act: Progress Update

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION

Standard Operating Procedures Guidelines for Good Clinical Practice

CDASH Clinical Data Acquisition Standards Harmonization

Implementing Standards

Transcription:

Background: ClincalTrials.gov and the database for Aggregate Analysis of ClincalTrials.gov (AACT)

Background! What is ClinicalTrials.gov?! ClinicalTrials.gov history! Key reporting requirements! Rationale for reporting clinical trials! Basic uses of ClinicalTrials.gov! Creation of AACT database

What is ClinicalTrials.gov?! ClinicalTrials.gov is a web site that provides patients, their family members, and health care professionals easy access to information about clinical studies on a range of diseases and conditions.! Information is provided and updated by the sponsor or principal investigator of a clinical study, and the web site is maintained by the U.S. National Library of Medicine (NLM) at the National Institutes of Health (NIH).

ClinicalTrials.gov History Date Event Description Nov 21, 1997 Feb 29, 2000 Sept 2004 Sept 27, 2007 Sept 23, 2008 Sept 28, 2009 Food and Drug Modernization Act of 1997 (FDAMA) section 113 enacted First version of ClinicalTrials.gov publicly available Internal Committee of Medical Journal Editors (ICMJE) policy established FDA Amendments Act (FDAAA) section 801 enacted Results reporting launched Adverse Event reporting required Mandated the creation of the ClinicalTrials.gov registry for efficacy trials in serious and life-threatening conditions and interventions regulated by the FDA Required studies published in their journals be registered in ClinicalTrials.gov or other equivalent publicly available registries Created a legal requirement for the registration of the trials of drugs, biologics, and devices Results reporting available, Adverse event reporting optional

Key Trial Reporting Requirements! Register at trial initiation for interventional studies of drugs, biologics, and devices (Phase 1 excluded)! Studies under an IND/IDE or with US site! To meet ICMJE requirement of registration http://www.icmje.org/recommendations/browse/publishingand-editorial-issues/clinical-trial-registration.html! Keep all entries up to date Changes are tracked on public site

Key Trial Results Reporting Requirements! Report summary results at trial completion for Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I investigations, of a product subject to FDA regulation Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation (other than small feasibility studies) and pediatric postmarket surveillance studies

Basic uses of ClinicalTrials.gov! Identify trials of potential interest for specific individual! Track progress of specific trial including access to summary results! Identify all trials that are ongoing or completed for a given set of conditions or interventions! Identify investigators and/or research centers participating in studies for given set of conditions or interventions

Database for the Aggregate Analysis of ClinicalTrials.gov (AACT) Design! Download XML dataset of all clinical studies registered with ClinicalTrials.gov as of March 27 and September 27 each year! Designed and implemented relational database to facilitate aggregate analysis of data Example Uses of Aggregate Data! Examine the Clinical Research Enterprise! Provide information to specific user communities! Examine the quality and completeness of reporting Further details: Tasneem A, et al. (2012) PLOS One 7(3): e33677. doi:10.1371/ journal.pone.0033677

! Aggregate Analysis of ClinicalTrials.gov (AACT)

Derived funding used in CTTI AACT Publications! Derived from Sponsor and Collaborators fields in ClinicalTrials.gov*: *For definitions see: http://prsinfo.clinicaltrials.gov/definitions.html

AACT Supporting Documents! Points to Consider: guidelines for investigators to consider when planning a statistical analysis using AACT! Comprehensive Data Dictionary: a complete list of data elements from the AACT database, corresponding definitions from NLM s data element definitions document, and data model and parameters used in the AACT database in five sections: current variables, enumerations, schema, constraints, and record counts.! Readme Files: instructions on how to implement AACT as well as critical info for database administrators and statistical programmers. http://www.ctti-clinicaltrials.org/what-we-do/analysis-dissemination/state-clinical-trials/aact-database

State of Clinical Trials! AACT is available in 3 formats: Oracle dmp, pipe-delimited text files, and SAS CPORT transport http://www.ctti-clinicaltrials.org/what-we-do/ analysis-dissemination/state-clinical-trials/aactdatabase! For an publications and products about AACT and created using the AACT database: http://www.ctti-clinicaltrials.org/what-we-do/ analysis-dissemination/state-clinical-trials/ products